NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on advancing surgical diagnosis and treatment of neurological disorders, has been added to the Russell Microcap Index, effective June 29, 2026. The inclusion follows the annual reconstitution of the Russell US Indexes, which ranks the 4,000 largest US stocks by market capitalization as of April 30.
The Russell Microcap Index comprises the smallest 1,000 securities in the Russell 2000 Index plus the next 1,000 smallest eligible securities. Being added to this index means NeuroOne is now part of a benchmark widely used by investment managers and institutional investors. According to FTSE Russell, approximately $12.2 trillion in assets were benchmarked against the Russell US indexes as of June 2025. This inclusion could increase the company's visibility and potentially attract investment from index funds that track these indexes.
“Membership in the Russell Microcap Index provides NeuroOne with greater exposure to the investment community,” the company stated. The reconstitution is based on objective market-capitalization rankings and style attributes, ensuring that the indexes remain representative of the US equity market.
NeuroOne markets innovative electrode technology platforms, including the Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These products have received FDA clearance and aim to reduce hospitalizations and surgical procedures while improving patient outcomes. The company also engages in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
For more information on the Russell Microcap Index and the reconstitution process, visit the FTSE Russell website. Additional details about NeuroOne and its technology can be found at nmtc1.com.
